TGFβ1-induced hepatocyte apoptosis involves the production of reactive oxygen species. An effective cellular defense mechanism against oxidative stress is the tripeptide glutathione (GSH), and the rate-limiting step in GSH biosynthesis is catalyzed by the heterodimeric holoenzyme glutamate cysteine ligase (GCL). Here, we demonstrate that TGFβ1-induced apoptosis in the TAMH murine hepatocyte cell line is accompanied by both the cleavage and loss of the catalytic subunit of GCL (GCLC) and the down-regulation of GCLC gene expression resulting in a reduction in GCL activity and depletion of intracellular GSH. TGFβ1-induced apoptosis is also accompanied by a reduction in Bcl-X L , an effect that may facilitate TGFβ1-induced apoptosis as Bcl-X L overexpression inhibits TGFβ1-induced caspase activation and cell death. Interestingly, Bcl-X L overexpression prevents TGFβ1-induced cleavage of GCLC protein but not downregulation of GCLC mRNA. Furthermore, TGFβ1-induced down-regulation of GCLC mRNA is prevented by inhibition of histone deacetylase activity, suggesting that this is an active repression of GCLC gene transcription. These findings suggest that the suppression of GSH antioxidant defenses associated with the caspase-dependent cleavage of GCLC protein, caspase-independent suppression of GCLC gene expression, and depletion of intracellular GSH may play a role in enhancing TGFβ1-induced oxidative stress and potentiating apoptotic cell death.
play an important role in mediating hepatocyte growth inhibition and apoptosis (2, 3) . TGFβ1 is a potent inhibitor of hepatocyte proliferation both in cultured hepatocytes and in the intact liver in vivo, causing growth arrest at concentrations as low as 0.1 ng/ml (4) (5) (6) . At higher doses (0.5-5 ng/ml) TGFβ1 induces apoptotic cell death in primary cultures of fetal and adult rat hepatocytes (7, 8) and hepatoma cells (9, 10) . This apoptotic response is physiologically relevant because in vivo delivery of active mature TGFβ1 causes hepatocyte apoptosis in the rat liver (11) (12) (13) . Despite significant advances in our understanding of the TGFβ1 signal transduction pathways (14) , the mechanism(s) mediating TGFβ1-induced apoptotic cell death in hepatocytes are not yet fully elucidated.
Many factors that induce hepatocyte apoptosis, including TGFβ1, cause mitochondrial dysfunction, which is characterized by a loss of mitochondrial membrane potential (∆Ψ m ) and the release of cytochrome c and other apoptogenic factors into the cytosol (15, 16) . The Bcl-2 family of antiapoptotic proteins, including Bcl-2 and Bcl-X L , function at the level of the mitochondria to prevent these responses and block mitochondrial-mediated apoptotic signaling in many cell types (15) . Several reports indicate that the down-regulation of Bcl-X L may facilitate mitochondrial damage during TGFβ1-induced hepatocyte apoptosis (8, 9, 17, 18) . However, while TGFβ1 induces the loss of ∆Ψ m and cytochrome c release, the involvement of Bcl-X L in the regulation of TGFβ1-induced apoptosis is still unclear. Several lines of evidence also indicate that TGFβ1-induced production of reactive oxygen species (ROS) initiates mitochondrial dysfunction and activation of the apoptotic machinery (8, 19, 20) . First, TGFβ1-induced ROS production precedes the loss of Bcl-X L and ∆Ψ m , cytochrome c release, and activation of caspase-3 (8) . Furthermore, free radical scavengers protect against TGFβ1-induced apoptosis and prevent mitochondrial dysfunction, caspase activation, and the loss of Bcl-X L (8, 19) . Interestingly, cycloheximide inhibits TGFβ1-induced ROS production and hepatocyte cell death, indicating that de novo synthesis of an as yet unknown protein is required for these responses (7, 21) . In addition to stimulating the generation of ROS, TGFβ1 induces the transcriptional downregulation of several antioxidative enzymes, including manganese-superoxide dismutase, copper/zinc-superoxide dismutase, catalase in primary rat hepatocytes (20) , and catalase and glutathione peroxidase in a pancreatic β-cell line (22) . These findings suggest that the functional inactivation of multiple antioxidant systems may potentiate TGFβ1-induced ROS production and oxidative damage during TGFβ1-induced apoptotic cell death.
TGFβ1-induced apoptosis in primary fetal rat hepatocytes is also associated with a reduction in intracellular glutathione (GSH) (8, 21) , which represents an additional antioxidant defense mechanism and is found at high levels within the liver (5-10 mM) (23) . Although depletion of intracellular GSH is a common feature in many models of hepatocyte apoptosis (16) , little is known concerning the regulation of GSH biosynthesis during apoptotic cell death. The first and rate-limiting step in GSH biosynthesis is catalyzed by glutamate cysteine ligase (GCL) (24) . GCL is a heterodimeric holoenzyme consisting of a catalytic subunit (GCLC), which contributes all the enzymatic activity of GCL, and a modifier subunit (GCLM), which regulates the affinity of GCL for substrates and inhibitors (24) . In this report, we demonstrate that TGFβ1-induced apoptosis in the TAMH murine hepatocyte cell line is accompanied by the cleavage of GCLC, loss of total GCLC protein expression, and a reduction in GCL enzymatic activity, which correlates temporally with the depletion of intracellular GSH. Furthermore, mitochondrial dysfunction appears to regulate these responses as overexpression of Bcl-X L blocks TGFβ1-induced apoptosis, cleavage and loss of GCLC protein, loss of GCL activity, and depletion of intracellular GSH. Analysis of GCLC gene expression suggests that caspase-independent transcriptional suppression of GCLC gene expression may also play a role in TGFβ1-induced loss of GCLC protein expression. These findings are consistent with a model in which the loss in GSH biosynthetic capacity and depletion of intracellular GSH associated with TGFβ1-induced cleavage and loss of GCLC protein enhance TGFβ1-induced oxidative stress and potentiate apoptotic cell death.
MATERIALS AND METHODS

Cell culture
The murine TAMH hepatocyte cell line established in this laboratory (25) was maintained in Dulbecco's modified Eagle medium/F12 media (Life Technologies, Grand Island, NY) supplemented with 5 µg/ml insulin, 5 µg/ml transferrin, 5 ng/ml selenium (ITS Premix, Collaborative Biomedical Products, Bedford, MA), 10 mM nicotinamide, 50 µg/ml gentamicin, and 0.1 µM dexamethasone. The TAMH/neo and TAMH/Bcl-X L cell lines stably expressing either vector alone or pSFFV-Bcl-X L , respectively, were obtained from Dr. David Hockenbery (Fred Hutchinson Cancer Research Center, Seattle, WA) (26) and were cultured in the presence of G418 (0.5 mg/ml). For all experiments, cells were seeded at 1.5 × 10 6 cells per 6-cm dish 18-24 h before treatment in the absence of G418.
Cell viability and caspase assays
Cell viability was assessed by trypan blue exclusion (27) . Caspase activities were measured using fluorogenic substrates as described previously (28, 29) . Cell extracts were prepared by a brief sonication on ice in TES/SB buffer (20 mM Tris, pH 7.4, 1 mM EDTA, 250 mM sucrose, 20 mM boric acid, 1 mM L-serine) supplemented with 1× Complete protease inhibitor cocktail (Roche Molecular Biochemicals, Indianapolis, IN). Lysates were centrifuged at 13,000g for 10 min at 4°C, and protein was quantitated by the Bradford assay (Bio-Rad, Hercules, CA). Soluble protein extract (5-25 µg) was added to an equal volume of 2× caspase cleavage buffer (40 mM PIPES, pH 7.2, 200 mM NaCl, 20% sucrose, 0.2% CHAPS, 20 mM DTT) containing 40 µM fluorogenic substrate (Ac-DEVD-AMC for caspase-3, Ac-IETD-AMC for caspase-8, and Ac-LEHD-AMC for caspase-9) (Alexis Biochemicals, San Diego, CA). Reactions were carried out at 37°C, and fluorescence was monitored on a Packard FluoroCount plate reader (Packard Instrument, Meriden, CT) with an excitation wavelength of 360 nm and an emission wavelength of 460 nm. Substrate autofluorescence was subtracted from each point, and specific activity was calculated against a standard curve of AMC (Sigma, St. Louis, MO), using the Packard I-Smart software. Samples were analyzed in duplicate, and data shown are the averages ±SE of at least three independent experiments.
Immunoblot analysis
Cells were harvested and lysed by sonication in TES/SB buffer as previously described. Equal amounts of protein were resolved on 10% SDS-PAGE gels and transferred to PVDF membranes (Millipore, Bedford, MA). Filters were blocked in Tris-buffered saline/0.1% Tween-20 (TBST) containing 5% milk and were then incubated with primary antibody in 0.5% milk/TBST. Membranes were probed for GCLC (29, 30) , GCLM (29) (30) (31) , Bid (R&D Systems, Minneapolis, MN), pro-caspase-3, active caspase-3 (BD PharMingen, San Diego, CA), or Bcl-X L (Santa Cruz Biotechnology, Santa Cruz, CA). Anti-mouse-HRP and anti-rabbit-HRP secondary antibodies (Amersham Pharmacia Biotech, Piscataway, NJ) were used at 1:5000 in 0.5% milk/TBST and anti-goat-HRP secondary antibody (Santa Cruz Biotechnology) was used at 1:2000 in 0.5% milk/TBST. Antigen-antibody complexes were detected by enhanced chemiluminescence as recommended by the manufacturer (Dupont-New England Nuclear, Boston, MA).
Glutathione and GCL activity assays
Total glutathione content (GSH + GSSG) was determined by a modification of the Tietze assay as described previously (29) . Cell extracts were prepared as described previously and processed as described previously (31) . GSH levels were determined against a standard curve of GSSG, and levels were calculated per microgram of soluble protein in the original cell extract. This value was subsequently used to determine the relative change in intracellular GSH levels compared with untreated samples. Data shown represent the averages ±SE of at least five experiments and are presented as percent change from untreated control cells. For GCL activity measurements, cells were harvested as described previously, except the pellets were washed in phosphate-buffered saline (PBS) before lysis to remove any traces of cysteine remaining from the media. Pellets were processed, and GCL specific activity was determined as described previously (30) .
Northern blots
Total RNA was isolated from cells using the RNeasy Mini kit (Qiagen, Santa Clarita, CA). RNA (15 µg) was resolved on 1% formaldehyde agarose gels and transferred to GeneScreen Plus membranes (Dupont-New England Nuclear). GCLC, GCLM, and GAPDH cDNA probes were generated as described previously (30) and were radiolabeled with (α-32 P)dCTP, using a Random Prime kit (Roche Molecular Biochemicals). The relative levels of GCLC, GCLM, and GAPDH mRNA were determined using a Storm phosphoimager (Molecular Dynamics, Sunnyvale, CA). GCLC and GCLM levels were normalized to GAPDH, and fold induction was calculated relative to untreated control cells.
RESULTS
Caspase activation and down-regulation of Bcl-X L during TGFβ1-induced apoptosis in murine TAMH hepatocyte cells
Studies from our laboratory and others have demonstrated that TGFβ1 induces apoptotic cell death in both established lines and primary cultures of hepatocytes (8, 13, 19, 21, 32, 33) . To examine the molecular mechanisms mediating TGFβ1-induced cell death, we used the established murine TAMH hepatocyte cell line (25) . TAMH cells were treated with TGFβ1 (5 ng/ml) for various periods of time, and cell death was assessed by trypan blue exclusion. Cell viability decreased in a time-dependent manner, with cell death being evident within 16 h of treatment and approaching 80% within 48 h (Fig. 1A) . Cell death was accompanied by the appearance of apoptotic morphology (i.e., condensed chromatin and cytoplasmic shrinkage) (data not shown). To confirm that TGFβ1-induced TAMH cell death was associated with activation of the apoptotic machinery, we analyzed whole cell extracts from TGFβ1-treated cells for various caspase-like activities, using fluorogenic substrates. TGFβ1 induced a timedependent increase in multiple caspase activities in TAMH cells (Fig. 1B) . TGFβ1-induced caspase-3-like DEVDase activity was detected within 8 h of treatment, with maximal activity occurring by 24-32 h. TGFβ1 induced a more gradual time-dependent increase in caspase-8-like IETDase and caspase-9-like LEHDase activities (Fig. 1B) . While the sequential order of caspase activation could not be accurately determined from these studies, TGFβ1-induced caspase activation correlated temporally with the appearance of apoptotic morphology (data not shown) and cell death (Fig. 1A) . Recent studies have demonstrated that Bcl-X L is down-regulated during TGFβ1-induced apoptosis in cultured hepatoma cells and primary hepatocytes (8, 9, 18) . TGFβ1 treatment resulted in a similar time-dependent decrease in Bcl-X L protein expression during TGFβ1-induced TAMH cell death (Fig. 1C) . Bcl-X L levels were reduced by 50-70% within 24 h of TGFβ1 treatment, which correlated temporally with caspase activation (Fig. 1B) . This finding is consistent with a model in which the down-regulation of Bcl-X L may contribute to TGFβ1-induced hepatocyte apoptosis.
Bcl-X L overexpression inhibits TGFβ1-induced caspase activation and TAMH cell death
To directly assess the putative role of Bcl-X L in the regulation of TGFβ1-induced cell death, we examined TGFβ1-induced apoptosis in a TAMH cell line stably overexpressing Bcl-X L (TAMH/Bcl-X L ) (26) . Steady-state Bcl-X L expression in the TAMH/Bcl-X L cell line ( (Fig. 2B) . Thus, the level of Bcl-X L protein expression plays a central role in regulating TAMH cell sensitivity to TGFβ1-induced apoptosis. These findings provide further support for the concept that the down-regulation of Bcl-X L facilitates TGFβ1-induced hepatocyte apoptosis.
Bcl-X L functions downstream of caspase-8 at the level of the mitochondrion to inhibit the release of cytochrome c into the cytosol and prevent the sequential activation of caspase-9 and caspase-3 during tumor necrosis factor (TNF)-α-and α-Fas-induced apoptosis (34, 35) . To determine whether Bcl-X L functions in a similar manner to inhibit TGFβ-induced TAMH cell apoptosis, we measured TGFβ1-induced caspase activities in the TAMH/neo and TAMH/Bcl-X L cell lines. TGFβ1 induced a time-dependent increase in caspase-3-like DEVDase activity (Fig. 2C, upper  panel) , caspase-8-like IETDase activity (middle panel), and caspase-9-like LEHDase activity (lower panel) in TAMH/neo cells, whereas only minimal increases were detected in the TAMH/Bcl-X L cell line. To verify that these caspases were activated during TGFβ1-induced TAMH cell death, we examined the cleavage of established endogenous caspase target proteins. To confirm that TGFβ1-induced DEVDase activity correlated with activation of caspase-3, we examined pro-caspase-3 processing by immunoblot analysis. TGFβ1 induced the time-dependent loss of the 32 kDa pro-caspase-3 in TAMH/neo cells (Fig. 2D, upper panel) , whereas no change in pro-caspase-3 levels was observed in the TAMH/Bcl-X L cell line (lower panel). TGFβ1 also induced the time-dependent appearance of the 17 kD active fragment of caspase-3 in TAMH/neo cells (Fig. 2D, upper panel) , but not in TAMH/Bcl-X L cells (lower panel). The immunoblot for active caspase-3 in the TAMH/Bcl-X L cell line was purposely overexposed to demonstrate that no active fragment was detectable. To confirm that caspase-8 was activated during TGFβ1-induced TAMH cell apoptosis, we examined the cleavage of the known caspase-8 substrate, Bid (36, 37) . There was a time-dependent decrease in the level of full-length Bid in the TAMH/neo cell line, which is indicative of processing by caspase-8 (Fig. 2D, upper panel) . In contrast, no change in Bid protein levels was observed in the TAMH/Bcl-X L cell line (Fig. 2D, lower panel) . These findings indicate that overexpression of Bcl-X L prevents TGFβ1-induced TAMH apoptotic cell death by inhibiting the activation of caspases that reside both upstream and downstream of mitochondrial dysfunction, suggesting the existence of a mitochondrial-mediated amplification loop in the TGFβ1-induced apoptotic signal transduction pathway.
Cleavage and loss of GCLC protein during TGFβ1-induced apoptosis
Fabregat and colleagues have reported that increased ROS production mediates TGFβ1-induced mitochondrial dysfunction and is required for hepatocyte apoptosis (8, 19) . TGFβ1-induced hepatocyte apoptosis is also accompanied by the depletion of intracellular GSH (8, 19, 21) , which may serve to enhance TGFβ1-induced oxidative damage and potentiate mitochondrialmediated apoptotic signaling. However, little is know about the regulation of GSH biosynthesis during TGFβ1-induced hepatocyte apoptosis. Therefore, we examined whether the expression and/or activity of the rate-limiting enzyme in GSH biosynthesis, GCL, was altered during TGFβ1-induced TAMH cell death. GCL is a heterodimeric enzyme consisting of a catalytic subunit (GCLC, 73 kDa) and a modifier subunit (GCLM, 31 kDa) (24) . Immunoblot analysis demonstrated that GCLC was cleaved from a full-length 73 kDa form to a 60 kDa form during TGFβ1-induced apoptosis (Fig. 3A, upper panel) , which correlated temporally with caspase activation (Fig. 1B) . Interestingly, in addition to the cleavage of GCLC, TGFβ1 treatment resulted in a time-dependent loss in total GCLC protein expression (Fig. 3A) . Similar results have been observed in response to TGFβ1 in the AML-12 and NMH hepatocyte cell lines established in this laboratory (data not shown) (25, 38) . This loss of total GCLC protein appears to be unique to TGFβ1-induced apoptotic cell death (29) . As shown in Fig. 3B , GCLC was also cleaved to a 60 kDa fragment during both TNF-α-and α-Fas-induced apoptosis in TAMH cells. However, total GCLC expression levels (cleaved + full-length protein) were unchanged. The decrease in total GCLC protein observed during TGFβ1-induced TAMH cell death was not due to a general inhibition of protein synthesis or loss of cytosolic protein due to cell lysis as TGFβ1 had no effect on the modifier subunit of GCL, GCLM (Fig. 3A, lower panel) .
TGFβ1-induced cleavage and loss of GCLC protein is associated with a reduction in GCL enzymatic activity and the depletion of intracellular GSH
Bcl-X L overexpression prevented TGFβ1-induced caspase activation and apoptosis in TAMH cells (Fig. 2) . Therefore, we used the TAMH/Bcl-X L cell line to determine whether caspase activation was required for TGFβ1-induced cleavage and loss of GCLC protein. Immunoblot analysis of GCLC in TGFβ1-treated TAMH/neo and TAMH/Bcl-X L cells indicated that Bcl-X L overexpression abolished TGFβ1-induced cleavage of GCLC protein and greatly attenuated the loss of GCLC protein (Fig. 4A) . To determine whether TGFβ1-induced cleavage and loss of GCLC protein had a functional effect on GSH biosynthesis, we measured GCL activity after TGFβ1 treatment. Treatment of TAMH/neo cells for 48 h with TGFβ1 resulted in a 70-80% reduction in GCL activity (Fig. 4B) . In contrast, TGFβ1 treatment resulted in only a slight decrease in GCL activity (20-30%) in the TAMH/Bcl-X L cell line (Fig. 4B) . To determine whether this loss of GSH biosynthetic capacity resulted in a reduction in intracellular GSH, we examined total cellular GSH levels (GSH + GSSG) following TGFβ1 treatment. TGFβ1 caused the time-dependent depletion of intracellular GSH levels in the TAMH/neo cell line (Fig. 4C) , which correlated temporally with the cleavage and loss of GCLC protein (Fig. 4A) . After 48 h of TGFβ1 treatment, when GCL activity was reduced to 20-30% of control, intracellular GSH levels had dropped to ∼20% of that measured in untreated control cells. In contrast, GSH levels remained unchanged throughout the time course of TGFβ1 treatment in the TAMH/Bcl-X L cell line (Fig. 4C) . These data suggest that caspase-mediated cleavage of GCLC and/or loss of GCLC protein expression result in a reduction in GCL activity that correlates with a depletion of intracellular GSH during TGFβ1-induced apoptosis in TAMH cells. Furthermore, Bcl-X L overexpression is sufficient to prevent TGFβ1-induced processing of GCLC and maintain GSH biosynthetic capacity and intracellular GSH homeostasis.
Cycloheximide inhibits TGFβ1-induced caspase activation and cleavage and loss of GCLC protein
In other models of death receptor-mediated apoptosis, inhibition of de novo protein synthesis with CHX is required for activation of the apoptotic machinery. In contrast, CHX prevents TGFβ1-induced caspase activation and apoptosis in fetal rat hepatocytes (7, 21) . We therefore examined whether CHX inhibited TGFβ1-induced apoptosis and proteolytic processing of GCLC protein in TAMH cells. Cells were pretreated with CHX (0.5 ug/ml) for 1 h before treatment with TGFβ1 for various time periods. Analysis of cell viability indicated that CHX pretreatment prevented TGFβ1-induced TAMH cell death (Fig. 5A) . The protection against TGFβ1-induced TAMH cell death was accompanied by a 60-70% decrease in TGFβ1-induced caspase-3-like DEVDase activity (Fig. 5B) , which correlated with a reduction in both the loss of pro-caspase-3 and the appearance of the 17 kDa active caspase-3 fragment (Fig. 5C ). CHX pretreatment resulted in a similar reduction in the activation of caspase-8-like IETDase activity and caspase-9-like LEHDase activity (data not shown) and also prevented TGFβ1-induced Bid cleavage and the loss of Bcl-X L protein expression (Fig. 5C) . Furthermore, CHX-mediated attenuation of caspase activation both attenuated TGFβ1-induced cleavage of GCLC protein and dramatically delayed the loss of total GCLC protein expression (Fig. 5C ). These findings provide further support that TGFβ1-induced caspase activation is required for the cleavage and loss of GCLC protein observed during TGFβ1-induced TAMH apoptotic cell death.
TGFβ1-induced suppression of GCLC gene expression occurs independently of caspase activation but requires histone deacetylase activity and de novo protein synthesis
Our finding that TGFβ1 treatment resulted in a loss of total GCLC protein expression during TAMH cell death led us to speculate that TGFβ1 might also regulate GCLC expression at the transcriptional level. To test this hypothesis, steady-state GCLC mRNA levels in TGFβ1-treated TAMH cells were assessed by Northern blot analysis. TGFβ1 treatment resulted in a rapid reduction in GCLC mRNA that was evident within 4 h (Fig. 6A) . In contrast, GCLM mRNA levels remained constant throughout the time course of TGFβ1 treatment (Fig. 6A) . To further elucidate the molecular mechanism(s) mediating TGFβ1-induced suppression of GCLC gene expression, we first examined the potential contribution of posttranscriptional effects on GCLC mRNA stability by determining the half-life of GCLC mRNA in TAMH cells treated with actinomycin D (ActD) in the absence and presence of TGFβ1. As shown in Figure 6B , TGFβ1 had no effect on the half-life of GCLC mRNA (∼4 h), suggesting that TGFβ1 decreases GCLC mRNA levels by inhibiting GCLC gene transcription. TGFβ1-induced transcriptional repression can occur through the recruitment of histone deacetylases (HDACs) to the transcriptional complex (39) . Two HDAC inhibitors, sodium butyrate and trichostatin A (TSA), were used to determine whether inhibition of HDAC activity would prevent TGFβ1-induced down-regulation of GCLC mRNA. Both sodium butyrate and TSA resulted in a dose-dependent reversal of TGFβ1-induced down-regulation of GCLC mRNA (Fig. 6C ), suggesting that a HDACdependent mechanism mediates TGFβ1-induced suppression of GCLC transcription. Our finding that CHX pretreatment delayed TGFβ1-induced loss of GCLC protein expression in parental TAMH cells (Fig. 5 ) led us to speculate that protein synthesis may also be required for TGFβ1-induced down-regulation of GCLC mRNA. Indeed, pretreatment with CHX abolished the TGFβ1-induced reduction in GCLC mRNA (Fig. 6D) , further supporting our hypothesis that this response may be dependent on the de novo synthesis of a transcriptional repressor.
Although these data indicate that TGFβ1 inhibits GCLC gene transcription, the rapid time course of TGFβ1-induced reduction in GCLC mRNA (within 4 h), which occurs before the appearance of caspase activity, suggests that caspase activation may not be involved in this response. To determine whether activation of the apoptotic machinery was necessary for TGFβ1-induced down-regulation of GCLC mRNA, GCLC mRNA levels were examined in TGFβ1-treated TAMH/Bcl-X L cells, which were resistant to TGFβ1-induced apoptosis. GCLC mRNA was down-regulated in a similar time-dependent manner in both TAMH/neo and TAMH/Bcl-X L cells (Fig. 7A) , confirming that caspase activation was not necessary for TGFβ1-induced downregulation of GCLC mRNA. To determine whether caspase activation was sufficient to induce the down-regulation of GCLC mRNA, several non-receptor-mediated apoptotic stimuli were examined for their ability to decrease GCLC mRNA. Although both cisplatin and trivalent arsenite induce caspase-mediated apoptosis in TAMH cells (unpublished observation, C.C.F.), these apoptotic stimuli had no effect on GCLC mRNA levels (Fig. 7B) . These results indicate that the down-regulation of GCLC mRNA is unique to TGFβ1 and is not a general phenomenon associated with all models of apoptotic cell death.
DISCUSSION
The aim of this study was to examine the molecular mechanisms mediating TGFβ1-induced hepatocyte apoptosis and determine whether glutathione biosynthesis was altered during execution of the cell death program. TGFβ1 treatment of TAMH murine hepatocyte cells resulted in the stimulation of caspase-3-like, caspase-8-like, and caspase-9-like activities culminating in apoptotic cell death. This profile of TGFβ1-induced caspase activation is consistent with that reported in human hepatoma cells (9, 10) , primary cultures of adult and fetal rat hepatocytes (7, 8) , and normal rat liver in vivo (11) . TGFβ1-induced apoptosis in TAMH cells is also accompanied by the cleavage of the proapoptotic Bid protein and a reduction in expression of the antiapoptotic Bcl-X L protein, both of which act at the level of the mitochondrion to regulate cytochrome c release and caspase-9 activation (15). Our finding that ectopic overexpression of Bcl-X L prevents TGFβ1-induced cell death supports a model in which down-regulation of endogenous Bcl-X L may be required for TGFβ1-induced hepatocyte apoptosis. Similar results were recently described in prostate epithelial cells (40) . It has also been proposed that caspase-8 is the apical caspase in initiating TGFβ1-induced activation of the caspase cascade (9). Although we were not able to definitively identify the sequential order of caspase activation by kinetic analysis in our cell model, the ability of Bcl-X L overexpression to prevent TGFβ1-induced caspase-8-like activity and cleavage of Bid suggests that mitochondrial dysfunction mediates these responses. Thus, although caspase-8 activation may be required to initiate TGFβ1-induced apoptotic signaling, mitochondrial-mediated amplification of caspase-8 activity may be necessary for the execution of cell death.
TGFβ1-induced generation of ROS is thought to play a primary role in initiating mitochondrial dysfunction and caspase activation during hepatocyte apoptosis (8, 19, 21, 41) . Furthermore, the deleterious effects of ROS production may be enhanced by TGFβ1-induced down-regulation of several antioxidative defense enzymes (20, 22) . TGFβ1-induced hepatocyte apoptosis is also associated with a depletion in the intracellular levels of the tripeptide antioxidant GSH, which plays a vital role in maintaining cellular redox status and protecting against oxidative injury in the liver. However, little is known about the mechanism(s) mediating the reduction in intracellular GSH. Here, we identify two distinct molecular mechanisms that contribute to the TGFβ1-induced loss of GSH homeostasis. We demonstrate that TGFβ1-induced apoptosis is accompanied by the cleavage and loss of GCLC protein, resulting in a decrease in GSH biosynthetic capacity. The correlation between TGFβ1-induced depletion of intracellular GSH and the loss of GCL activity suggests a causal relationship between these two events, which is supported by our finding that GSH homeostasis is maintained in TGFβ1-treated TAMH/Bcl-X L cells when only a minimal loss in GCL activity is observed. These findings suggest a novel mechanism whereby TGFβ1 induces the caspase-dependent cleavage and loss of GCLC protein, which dramatically reduces cellular GSH biosynthetic capacity. This results in the depletion of intracellular GSH, which may play a role in enhancing TGFβ1-induced oxidative stress and potentiating apoptotic cell death.
In addition to the posttranslational processing of GCLC protein, TGFβ1 treatment also caused the rapid down-regulation of GCLC mRNA, suggesting that suppression of GCLC gene expression may also be involved in the TGFβ1-induced decrease in total GCLC protein expression. TGFβ1 does not induce the posttranscriptional destabilization of GCLC mRNA, which is consistent with recent studies in A549 human alveolar epithelial cells (42, 43) . Furthermore, inhibition of protein synthesis or HDAC activity prevented TGFβ1-induced suppression of GCLC gene expression, indicating that this is an active repression of GCLC transcription that requires de novo protein synthesis. Interestingly, although TGFβ1 induced the caspase-dependent cleavage of GCLC, activation of the apoptotic machinery per se was not necessary or sufficient for TGFβ1-induced suppression of GCLC gene expression. The caspaseindependent nature of this transcriptional repression suggests that TGFβ1-induced suppression of GCLC expression and loss of GSH homeostasis may also be involved in chronic TGFβ1-induced responses in the liver that do not involve apoptotic cell death, such as fibrosis and growth inhibition.
TGFβ1-receptor activation results in the phosphorylation of Smad2 and Smad3, which form a heteromeric complex with Smad4 that is translocated to the nucleus and regulates target gene expression by binding directly to the Smad binding element (SBE; CAGA-box) (14) . Analysis of the human GCLC promoter indicates the presence of multiple CAGA-box sequences (44), many of which are conserved within the murine GCLC promoter (unpublished data, T.J.K.), which could potentially mediate TGFβ1-induced repression of GCLC transcription. Smad-dependent transcriptional repression is thought to involve the recruitment of transcriptional corepressors to the Smad transcriptional complex (39) . Transcriptional repression is then achieved through the recruitment of HDACs, which induce chromatin condensation and reduce accessibility to the transcriptional machinery (39) . Our finding that HDAC inhibitors prevent TGFβ1-induced suppression of GCLC gene expression is consistent with this model and demonstrates that a HDAC-dependent transcriptional repressor mediates TGFβ1-induced inhibition of GCLC transcription. Furthermore, the ability of CHX to prevent TGFβ1-induced down-regulation of GCLC mRNA suggests that a newly synthesized protein mediates this response. Although the identity of this factor is not known, it is interesting to speculate that members of the TGFβ1-inducible early gene family (TIEG) may function as the TGFβ1-inducible transcriptional repressors. The TIEG family of transcription factors are TGFβ1-inducible Sp1-like zinc finger proteins that contain three conserved transcriptional repressor domains capable of recruiting the mSin3A histone deacetylase and repressing promoter activity by binding to Sp1-like DNA sequences (45, 46) . Importantly, a GC-rich region surrounding the TATA box of the GCLC promoter contains several consensus Sp1 binding sites (47) , and this proximal promoter region is sufficient for constitutive expression of GCLC in HepG2 cells (44) . Additional studies are necessary to identify the promoter regions and factors involved in mediating TGFβ1-induced repression of GCLC transcription.
Although the down-regulation of GCLC mRNA likely contributes to the reduction in GCLC protein during TGFβ1-induced apoptosis, suppression of GCLC gene expression alone cannot account for the dramatic loss of GCLC protein in the absence of protein turnover. This is highlighted by the ability of TGFβ1 to efficiently down-regulate GCLC mRNA levels in TAMH/Bcl-X L cells, while causing only a slight decrease in GCLC protein expression. Furthermore, although caspase-mediated cleavage of GCLC may play a role in promoting the loss in total GCLC protein expression during TGFβ1-induced apoptosis, GCLC is cleaved to a stable 60 kDa fragment during TNF-α-and α-Fas-induced apoptosis in TAMH cells (Fig. 3 and  ref 29) . Thus, an additional TGFβ1-induced signal is required for the rapid loss of total GCLC protein expression. TGFβ1 targets several SMAD proteins, the TGFβ receptor, and p57
Kip2 for ubiquitination and proteasome-mediated degradation (48) (49) (50) (51) (52) , and it is possible that a similar mechanism mediates TGFβ1-induced degradation of GCLC. Attempts to examine this possibility using the proteasome inhibitors MG132 and lactacystin were hindered due to their inherent cytotoxicity in TAMH cells (data not shown). However, recent reports indicate that GCLC expression can be regulated by proteasome activity (53, 54) . Our findings that TGFβ1-induced loss of GCLC protein is dramatically attenuated by CHX pretreatment and that only a minimal loss of GCLC is observed in TAMH/Bcl-X L cells suggest that caspase-mediated cleavage of GCLC may be required for subsequent degradation, as described for the proapoptotic truncated form of Bid (55) and the atypical protein kinase Cζ (56) . Although no cleavage of GCLC was detected in TGFβ1-treated TAMH/Bcl-X L cells, a slight reduction in GCLC protein expression and GCL activity was routinely observed over the time period analyzed (48 h), which is likely due to the caspase-independent suppression of GCLC transcription. In light of these findings, it is interesting to speculate that although chronic TGFβ1 treatment might lead to a gradual loss of GCLC protein in the absence of caspase activation, caspase-mediated cleavage of GCLC may function to ensure its rapid degradation during TGFβ1-induced apoptotic cell death. (27) . Data shown are the averages ±SE of a representative experiment performed in triplicate. C) Whole-cell extracts were prepared from identically treated cells, and caspase activities were measured using fluorogenic substrates as described in Figure 1 . The data shown are the averages ±SE of three to seven independent experiments. D) Similar extracts were used for immunoblot analysis of the loss of pro-caspase-3 (upper panels), the appearance of the active 17-kDa fragment of caspase-3 (middle panels), and the cleavage and loss of Bid (lower panels). The top sets of panels are from TAMH/neo cells, and the bottom sets of panels are from TAMH/Bcl-X L cells. Whole-cell extracts were prepared, and GCLC protein expression was assessed by immunoblot analysis. B) TAMH/neo and TAMH/Bcl-X L cells were treated with TGFβ (5 ng/ml) for 48 h as indicated. Whole-cell extracts were prepared and analyzed for GCL enzymatic activity as described in Materials and Methods. Results shown are the averages ±SE of three experiments. C) TAMH/neo (closed bars) and TAMH/Bcl-X L (open bars) cells were treated with TGFβ for the times indicated, and total intracellular glutathione levels (GSH+GSSG) were measured by a modified Tietze assay (29) . The data shown are averages ±SE of five experiments. the absence or presence of TGFβ1 (5 ng/ml) for the times indicated. B) TAMH cells were treated with actinomycin D (ActD; 250 ng/ml) in the absence or presence of TGFβ1 (5 ng/ml) for the times indicated. C) TAMH cells were treated for 8 h with TGFβ1 (5 ng/ml) in the presence of increasing concentrations of sodium butyrate (Na-But; mM) or trichostatin A (TSA; uM) as indicated. D) TAMH cells were preincubated for 1 h with cycloheximide (CHX; 0.5 ug/ml) before treatment for 8 h with TGFβ1 (5 ng/ml) as indicated. Total RNA was isolated, and GCLC, GCLM, and GAPDH mRNA were assessed by Northern blot analysis. Relative mRNA levels were quantitated, and GCLC (closed bars) and GCLM (open bars) levels were normalized to GAPDH mRNA. Ratios are presented in graphical form, and the data presented are representative of at least three experiments. A) TAMH/neo and TAMH/Bcl-X L cells were incubated in the absence or presence of TGFβ1 (5 ng/ml) for the times indicated. B) Parental TAMH cells were untreated (NA) or treated for 16 h with either TGFβ1 (T; 5 ng/ml) or cisplatin (C; 50 uM) or for 8 h with As 3+ (A; 10 uM). Total RNA was isolated, and GCLC mRNA and GAPDH mRNA were assessed by Northern blot analysis. Relative mRNA levels were quantitated, and GCLC levels were normalized to GAPDH mRNA. Results are presented in graphical form for each experiment, and the data presented are representative of at least three experiments.
